Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Panobinostat in Refractory/Resistant Cutaneous T-Cell Lymphoma
NCT00490776Phase 2Terminated
- Sponsor
- Novartis
- Start
- Jul 2007
- Primary completion
- Sep 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of panobinostat in cutaneous T-cell lymphoma (CTCL), sponsored by Novartis. Primary endpoint: Overall Response Rate up to 2 years. Started Jul 2007; status: terminated.
02
Drugs
panobinostat
03
Conditions
cutaneous T-cell lymphoma (CTCL)
Beyond the preview
Go deeper on NCT00490776.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00490776.